Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

608 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epigenome-based cancer risk prediction: rationale, opportunities and challenges.
Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Widschwendter M, et al. Among authors: colombo n. Nat Rev Clin Oncol. 2018 May;15(5):292-309. doi: 10.1038/nrclinonc.2018.30. Epub 2018 Feb 27. Nat Rev Clin Oncol. 2018. PMID: 29485132 Review.
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.
Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RH, Sonke GS, Colombo N, Špaček J, Vuylsteke P, Hirte H, Mahner S, Plante M, Schmalfeldt B, Mackay H, Rowbottom J, Lowe ES, Dougherty B, Barrett JC, Friedlander M. Oza AM, et al. Among authors: colombo n. Lancet Oncol. 2015 Jan;16(1):87-97. doi: 10.1016/S1470-2045(14)71135-0. Epub 2014 Dec 4. Lancet Oncol. 2015. PMID: 25481791 Clinical Trial.
Follow-up in Gynecological Malignancies: A State of Art.
Zola P, Macchi C, Cibula D, Colombo N, Kimmig R, Maggino T, Reed N, Kesic V. Zola P, et al. Among authors: colombo n. Int J Gynecol Cancer. 2015 Sep;25(7):1151-64. doi: 10.1097/IGC.0000000000000498. Int J Gynecol Cancer. 2015. PMID: 26207784 Review.
Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study.
Nené NR, Reisel D, Leimbach A, Franchi D, Jones A, Evans I, Knapp S, Ryan A, Ghazali S, Timms JF, Paprotka T, Bjørge L, Zikan M, Cibula D, Colombo N, Widschwendter M. Nené NR, et al. Among authors: colombo n. Lancet Oncol. 2019 Aug;20(8):1171-1182. doi: 10.1016/S1470-2045(19)30340-7. Epub 2019 Jul 9. Lancet Oncol. 2019. PMID: 31300207
Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial.
Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA 3rd, Bidziński M, Kim JW, Nam JH, Madry R, Hernández C, Mora PAR, Ryu SY, Milenkova T, Lowe ES, Barker L, Scambia G. Penson RT, et al. Among authors: colombo n. J Clin Oncol. 2020 Apr 10;38(11):1164-1174. doi: 10.1200/JCO.19.02745. Epub 2020 Feb 19. J Clin Oncol. 2020. PMID: 32073956 Free PMC article. Clinical Trial.
DNA methylation signatures to predict the cervicovaginal microbiome status.
Nené NR, Barrett J, Jones A, Evans I, Reisel D, Timms JF, Paprotka T, Leimbach A, Franchi D, Colombo N, Bjørge L, Zikan M, Cibula D, Widschwendter M. Nené NR, et al. Among authors: colombo n. Clin Epigenetics. 2020 Nov 23;12(1):180. doi: 10.1186/s13148-020-00966-7. Clin Epigenetics. 2020. PMID: 33228781 Free PMC article.
The WID-BC-index identifies women with primary poor prognostic breast cancer based on DNA methylation in cervical samples.
Barrett JE, Herzog C, Jones A, Leavy OC, Evans I, Knapp S, Reisel D, Nazarenko T, Kim YN, Franchi D, Ryan A, Franks J, Bjørge L, Zikan M, Cibula D, Harbeck N, Colombo N, Dudbridge F, Jones L, Sundström K, Dillner J, Rådestad AF, Gemzell-Danielsson K, Pashayan N, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Nat Commun. 2022 Feb 1;13(1):449. doi: 10.1038/s41467-021-27918-w. Nat Commun. 2022. PMID: 35105882 Free PMC article.
Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Genome Biol. 2022 Feb 22;23(1):52. doi: 10.1186/s13059-022-02603-3. Genome Biol. 2022. PMID: 35189945 Free PMC article.
Author Correction: Susceptibility to hormone-mediated cancer is reflected by different tick rates of the epithelial and general epigenetic clock.
Barrett JJE, Herzog C, Kim YN, Bartlett TE, Jones A, Evans I, Cibula D, Zikan M, Bjørge L, Harbeck N, Colombo N, Howell SJ, Rådestad AF, Gemzell-Danielsson K, Widschwendter M. Barrett JJE, et al. Among authors: colombo n. Genome Biol. 2022 Jun 29;23(1):142. doi: 10.1186/s13059-022-02704-z. Genome Biol. 2022. PMID: 35768851 Free PMC article. No abstract available.
The WID-EC test for the detection and risk prediction of endometrial cancer.
Barrett JE, Jones A, Evans I, Herzog C, Reisel D, Olaitan A, Mould T, MacDonald N, Doufekas K, Newton C, Crosbie EJ, Bjørge L, Colombo N, Dostalek L, Costas L, Peremiquel-Trillas P, Ponce J, Matias-Guiu X, Zikan M, Cibula D, Wang J, Sundström K, Dillner J, Widschwendter M. Barrett JE, et al. Among authors: colombo n. Int J Cancer. 2023 May 1;152(9):1977-1988. doi: 10.1002/ijc.34406. Epub 2023 Jan 17. Int J Cancer. 2023. PMID: 36533702 Free article.
608 results